Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Treasury Shares: 2019-2025

Historic Treasury Shares for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $16.6 million.

  • Allogene Therapeutics' Treasury Shares rose 25.29% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year increase of 25.29%. This contributed to the annual value of $13.3 million for FY2024, which is 9.55% up from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Treasury Shares is $16.6 million, which was down 3.43% from $17.2 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Treasury Shares high stood at $18.1 million for Q1 2025, and its period low was $3.1 million during Q1 2021.
  • Its 3-year average for Treasury Shares is $14.2 million, with a median of $13.3 million in 2024.
  • Data for Allogene Therapeutics' Treasury Shares shows a peak YoY soared of 146.50% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Treasury Shares stood at $4.3 million in 2021, then grew by 28.92% to $5.5 million in 2022, then soared by 121.73% to $12.2 million in 2023, then increased by 9.55% to $13.3 million in 2024, then rose by 25.29% to $16.6 million in 2025.
  • Its last three reported values are $16.6 million in Q3 2025, $17.2 million for Q2 2025, and $18.1 million during Q1 2025.